WCLC 2020: Tagrisso significantly extends the disease-free survival of non-small cell lung patients with EGFR mutations

Depending on the appearance under the microscope, lung cancer can be divided into two broad categories: small cell lung cancer and non-small cell lung cancer.
non-small cell lung cancer, which currently accounts for about 87% of lung cancer cases.
, presented at the WCLC 2020 conference, showed that non-small cell lung cancer patients maintained a quality of life in the ADAURA Phase III trial.
new data demonstrate Tagrisso's ability to penetrate the blood-brain barrier of the central nervous system in patients with metastasis.
results from the ADAURA Phase III clinical trial showed that AstraZeneta's Tagrisso (osimertinib) extended the disease-free survival (DFS) in patients with skin growth factor subject mutation (EGFRm) non-small cell lung cancer (NSCLC).
In an exploratory analysis of the entire trial population, Tagrisso aids reduced the risk of recurrence or death by 84% in patients who received complementary chemotherapy (risk ratio of 0.16, 95% confidence interval 0.10-0.26).
, the benefits of DFS are similar at each stage of the disease.
In addition, the researchers conducted a separate ex post facto exploratory analysis of the outcomes reported by patients, which showed that patients treated with Tagrisso were able to maintain their quality of life, and that there was no clinical difference in physical or mental health indicators between patients in the Tagrisso group and the placebo group.